Role of genetic polymorphisms in ovarian cancer susceptibility: Development of an international ovarian cancer association consortium

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 53-67

  Berchuck, Andrew ^a   Schildkraut, Joellen M ^a   Pearce, C Leigh ^a   Chenevix Trench, Georgia ^a   Pharoah, Paul D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DNA; ESTROGEN; INTERLEUKIN 1 RECEPTOR AGONIST; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROGESTERONE; PROSTAGLANDIN SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

CANCER EPIDEMIOLOGY; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DIAGNOSTIC VALUE; EPIDEMIOLOGY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL COOPERATION; ONCOGENE; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CLINICAL TRIALS AS TOPIC; EPIDEMIOLOGY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS; HUMANS; INTERNATIONAL AGENCIES; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 84934438988     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_5     Document Type: Review

References (60)

1. Risch, N. and Merikangas, K. The future of genetic studies of complex human diseases, Science, 273: 1516-1517, 1996.
2. Whittemore, A.S., Harris, R. and Itnyre, J. Characteristics relating to ovarian cancer risk. Collaborative analysis of twelve US case-control studies. II. Invasive epithelial ovarian cancers in white women, Am J Epidemiol, 136: 1184-1203, 1992.
3. Risch, H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone, J Natl Cancer Inst, 90: 1774-1786, 1998.
4. Rodriguez, G.C., Walmer, D.K., Cline, M., Krigman, H.R., Lessey, B.A., Whitaker, R.S., Dodge, R.K. and Hughes, C.L. Effect of progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis? J Soc Gynecol Invest, 5: 271-276, 1998.
5. Rodriguez, G.C., Nagarsheth, N.P., Lee, K.L., Bentley, R.C., Walmer, D.K., Cline, M., Whitaker, R.S., Isner, P., Berchuck, A., Dodge, R.K. and Hughes, C.L. Progestin-induced apoptosis in the macaque ovarian epithelium: Differential regulation of transforming growth factor-beta, J Natl Cancer Inst, 94: 50-60, 2002.
6. Schildkraut, J.M., Calingaert, B., Marchbanks, P.A., Moorman, P.G. and Rodriguez, G.C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk, J Natl Cancer Inst, 94: 32-38, 2002.
7. Pike, M.C., Pearce, C.L., Peters, R., Cozen, W., Wan, P. and Wu, A.H. Hormonal factors and the risk of invasive ovarian cancer: A population-based case-control study, Fertil Steril, 82:186-95, 2004.
8. Ness, R.B. Endometriosis and ovarian cancer: Thoughts on shared pathophysiology, Am J Obstet Gynecol, 189: 280-294, 2003.
9. Lefkowitz, E.S. and Garland, C.F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women, Int J Epidemiol, 23: 1133-1136, 1994.
10. Fairfield, K.M., Hunter, D.J., Fuchs, C.S., Colditz, G.A. and Hankinson, S.E. Aspirin, other NSAIDs, and ovarian cancer risk, Cancer Causes Control, 13: 535-542, 2002.
11. Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A. and Hemminki, K. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland, N Engl J Med, 343: 78-85, 2000.
12. Berchuck, A., Schildkraut, J.M., Marks, J.R. and Futreal, P.A. Managing hereditary ovarian cancer risk, Cancer, 86: 2517-2524, 1999.
13. Frank, T.S., Manley, S.A., Olopade, O.I., Cummings, S., Garber, J.E., Bernhardt, B., Antman, K., Russo, D., Wood, M.E., Mullineau, L., Isaacs, C., Peshkin, B., Buys, S., Venne, V., Rowley, P.T., Loader, S., Offit, K., Robson, M., Hampel, H., Brener, D., Winer, E.P., Clark, S., Weber, B., Strong, L.C. and Thomas, A. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk, J Clin Oncol, 16: 2417-2425, 1998.
14. Couch, F.J. and Weber, B.L. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene, Hum Mutat, 8: 8-18, 1996.
15. Shattuck-Eidens, D., Oliphant, A., McClure, M., McBride, C., Gupte, J., Rubano, T., Pruss, D., Tavtigian, S.V., Teng, D.H., Adey, N., Staebell, M., Gumpper, K., Lundstrom, R., Hulick, M., Kelly, M., Holmen, J., Lingenfelter, B., Manley, S., Fujimura, F., Luce, M., Ward, B., Cannon-Albright, L., Steele, L., Offit, K., Thomas, A., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing, JAMA, 278: 1242-1250, 1997.
16. Whittemore, A.S., Gong, G. and Itnyre, J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer, Am J Hum Genet, 60: 496-504, 1997.
17. Struewing, J.P., Hartge, P., Wacholder, S., Baker, S.M., Berlin, M., McAdams, M., Timmerman, M.M., Brody, L.C. and Tucker, M.A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336: 1401-1408, 1997.
18. Risch, H.A., McLaughlin, J.R., Cole, D.E., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D.J., Kuperstein, G., Abrahamson, J.L., Fan, I., Wong, B. and Narod, S.A. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer, Am J Hum Genet, 68: 700-710, 2001.
19. Szabo, C.I. and King, M.C. Invited editorial: Population genetics of BRCA1 and BRCA2, Am J Hum Genet, 60: 1013-1020, 1997.
20. Guillem, J., Wood, W., Berchuck, Karlan, B., Mutch, D., Gagel, R., Weitzel, J., Morrow, M., Weber, B., Giardiello, F., Rodriguez-Bigas, M., Church, J., Gruber, S. and Offit, K. ASCO/ SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes, J Clin Oncol, 24: 4642-60, 2006.
21. Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Shaw, N., Lane, C.R., Lim, E.P., Kalyanaraman, N., Nemesh, J., Ziaugra, L., Friedland, L., Rolfe, A., Warrington, J., Lipshutz, R., Daley, G.Q. and Lander, E.S. Characterization of single-nucleotide polymorphisms in coding regions of human genes, Nat Genet, 22: 231-8, 1999.
22. Halushka, M.K., Fan, J.B., Bentley, K., Hsie, L., Shen, N., Weder, A., Cooper, R., Lipshutz, R. and Chakravarti, A. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis, Nat Genet, 22: 239-47, 1999.
23. Sachidanandam, R., Weissman, D., Schmidt, S.C., Kakol, J.M., Stein, L.D., Marth, G., Sherry, S., Mullikin, J.C., Mortimore, B.J., Willey, D.L., Hunt, S.E., Cole, C.G., Coggill, P.C., Rice, C. M., Ning, Z., Rogers, J., Bentley, D.R., Kwok, P.Y., Mardis, E.R., Yeh, R.T., Schultz, B., Cook, L., Davenport, R., Dante, M., Fulton, L., Hillier, L., Waterston, R.H., McPherson, J.D., Gilman, B., Schaffner, S., Van Etten, W.J., Reich, D., Higgins, J., Daly, M.J., Blumenstiel, B., Baldwin, J., Stange-Thomann, N., Zody, M.C., Linton, L., Lander, E.S. and Altshuler, D. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, 409: 928-33, 2001.
24. The International HapMap Project, Nature, 426: 789-96, 2003.
25. Carlson, C.S., Eberle, M.A., Kruglyak, L. and Nickerson, D.A. Mapping complex disease loci in whole-genome association studies, Nature, 429: 446-452, 2004.
26. McKenna, N.J., Kieback, D.G., Carney, D.N., Fanning, M., McLinden, J. and Headon, D.R. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma, Br J Cancer, 71: 451-455, 1995.
27. Rowe, S.M., Coughlan, S.J., McKenna, N.J., Garrett, E., Kieback, D.G., Carney, D.N. and Headon, D.R. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion, Cancer Res, 55: 2743-2745, 1995.
28. Spurdle, A.B., Webb, P.M., Purdie, D.M., Chen, X., Green, A. and Chenevix-Trench, G. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer, Carcinogenesis, 22: 717-721, 2001.
29. Lancaster, J.M., Berchuck, A., Carney, M., Wiseman, R.W. and Taylor, J.A. Progesterone receptor gene and risk of breast and ovarian cancer, Br J Cancer, 78: 277, 1997.
30. Manolitsas, T.P., Englefield, P., Eccles, D.M. and Campbell, I.G. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer, Br J Cancer, 75: 1398-1399, 1900.
31. Lancaster, J.M., Wenham, R.M., Halabi, S., Calingaert, B., Marks, J.R., Moorman, P.G., Bentley, R.C., Berchuck, A. and Schildkraut, J.M. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina, Cancer Epidemiol Biomarkers Prev, 12: 226-227, 2003.
32. Pearce, C.L., Hirschhorn, J.N., Wu, A.H., Burtt, N.P., Stram, D.O., Young, S., Kolonel, L.N., Henderson, B.E., Altshuler, D. and Pike, M.C. Clarifying the PROGINS allele association in ovarian and breast cancer risk: A haplotype-based analysis, J Natl Cancer Inst, 97: 51-59, 2005.
33. Berchuck, A., Schildkraut, J.M., Wenham, R.M., Calingaert, B., Ali, S., Henriott, A., Halabi, S., Rodriguez, G.C., Gertig, D., Purdie, D.M., Kelemen, L., Spurdle, A.B., Marks, J. and Chenevix-Trench, G. Progesterone receptor promoter +331A polymorphism is associated with increased risk of endometrioid and clear cell ovarian cancers, Cancer Epidemiol Biomarkers Prev, 13: 2141-2147, 2004.
34. Spurdle, A.B., Webb, P.M., Chen, X., Martin, N.G., Giles, G.G., Hopper, J.L. and Chenevix- Trench, G. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer, Int J Cancer, 87: 637-643, 2000.
35. Levine, D.A. and Boyd, J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series, Cancer Res, 61: 908-911, 2001.
36. Garner, E.I., Stokes, E.E., Berkowitz, R.S., Mok, S.C. and Cramer, D.W. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer, Cancer Res, 62: 3058-3062, 2002.
37. Spurdle, A.B., Chen, X., Abbazadegan, M., Martin, N., Khoo, S.K., Hurst, T., Ward, B., Webb, P.M. and Chenevix-Trench, G. CYP17 promotor polymorphism and ovarian cancer risk, Int J Cancer, 86: 436-439, 2000.
38. Runnebaum, I.B., Tong, X.W., Konig, R., Zhao, H., Korner, K., Atkinson, E.N., Kreienberg, R., Kieback, D.G. and Hong, Z.c.t.Z.H. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer, Lancet, 345: 994, 1995.
39. Lancaster, J.M., Brownlee, H.A., Wiseman, R.W. and Taylor, J. p53 polymorphism in ovarian and bladder cancer, Lancet, 346: 182, 1995.
40. Spurdle, A.B., Purdie, D., Chen, X. and Chenevix-Trench, G. The prohibitin 3 untranslated region polymorphism is not associated with risk of ovarian cancer, Cancer Res, 90: 145-149, 2003.
41. Lancaster, J.M., Taylor, J.A., Brownlee, H.A., Bell, D.A., Berchuck, A. and Wiseman, R.W. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer, Mol Carcinog, 17: 160-162, 1996.
42. Spurdle, A.B., Purdie, D.M., Webb, P.M., Chen, X., Green, A. and Chenevix-Trench, G. The microsomal epoxide hydrolase Tyr113His polymorphism: Association with risk of ovarian cancer, Mol Carcinog, 30: 71-78, 2001.
43. Auranen, A., Spurdle, A.B., Chen, X., Lipscombe, J., Purdie, D.M., Hopper, J.L., Green, A., Healey, C.S., Redman, K., Dunning, A.M., Pharoah, P.D., Easton, D.F., Ponder, B.A., Chenevix-Trench, G. and Novik, K.L. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk, Int J Cancer, 103: 427-430, 2003.
44. Wenham, R.M., Schildkraut, J.M., McLean, K., Calingaert, B., Bentley, R.C., Marks, J.R. and Berchuck, A. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer, Clin Cancer Res, 9: 4396-4403, 2003.
45. Thomas, D.C. and Witte, J.S. Point: Population stratification: A problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev, 11: 505-512, 2002.
46. Healey, C.S., Dunning, A.M., Teare, M.D., Chase, D., Parker, L., Burn, J., Chang-Claude, J., Mannermaa, A., Kataja, V., Huntsman, D.G., Pharoah, P.D., Luben, R.N., Easton, D.F. and Ponder, B.A. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability, Nat Genet, 26: 362-364, 2000.
47. Durocher, F., Shattuck-Eidens, D., McClure, M., Labrie, F., Skolnick, M.H., Goldgar, D.E. and Simard, J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations, Hum Mol Genet, 5: 835-842, 1996.
48. Dunning, A.M., Chiano, M., Smith, N.R., Dearden, J., Gore, M., Oakes, S., Wilson, C., Stratton, M., Peto, J., Easton, D., Clayton, D. and Ponder, B.A. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population, Hum Mol Genet, 6:285-289, 1997.
49. Janezic, S.A., Ziogas, A., Krumroy, L.M., Krasner, M., Plummer, S.J., Cohen, P., Gildea, M., Barker, D., Haile, R., Casey, G. and Anton-Culver, H. Germline BRCA1 alterations in a population- based series of ovarian cancer cases, Hum Mol Genet, 8: 889-897, 1999.
50. Agoulnik, I.U., Tong, X.W., Fischer, D.C., Korner, K., Atkinson, N.E., Edwards, D.P., Headon, D.R., Weigel, N.L. and Kieback, D.G. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk, J Clin Endocrinol Metab, 89: 6340-6347, 2004.
51. DeVivo, I, Huggins, G.S., Hankinson, S.E., Lescault, P.J., Boezen, M., Colditz, G.A. and Hunter, D.J. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk, Proc Natl Acad Sci USA, 99: 12263-12268, 2002.
52. Giangrande, P.H., Kimbrel, E.A., Edwards, D.P. and McDonnell, D.P. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding, Mol Cell Biol, 20: 3102-3115, 2000.
53. DeVivo, I., Hankinson, S.E., Colditz, G.A. and Hunter, D.J. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk, Cancer Res, 63: 5236-5238, 2003.
54. Feigelson, H.S., Rodriguez, C., Jacobs, E.J., Diver, W.R., Thun, M.J. and Calle, E.E. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer, Cancer Epidemiol Biomarkers Prev, 13: 1084-5, 2004.
55. Lohmueller, K.E., Pearce, C.L., Pike, M., Lander, E.S. and Hirschhorn, J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease, Nat Genet, 33: 177-82, 2003.
56. Conti, D.V., Cortessis,V., Molitor, J. and Thomas, D.C. Bayesian modeling of complex metabolic pathways, Hum Hered, 56: 83-93, 2003.
57. Conti, D.V. and Gauderman, W.J. SNPs, haplotypes, and model selection in a candidate gene region: The SIMPle analysis for multilocus data, Genet Epidemiol, 27: 429-41, 2004.
58. Stram, D.O., Haiman, C.A., Hirschhorn, J.N., Altshuler, D., Kolonel, L.N., Henderson, B.E. and Pike, M.C. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study, Hum Hered, 55: 27-36, 2003.
59. Johnson, G.C., Esposito, L., Barratt, B.J., Smith, A.N., Heward, J., Di Genova, G., Ueda, H., Cordell, H.J., Eaves, I.A., Dudbridge, F., Twells, R.C., Payne, F., Hughes, W., Nutland, S., Stevens, H., Carr, P., Tuomilehto-Wolf, E., Tuomilehto, J., Gough, S.C., Clayton, D.G. and Todd, J.A. Haplotype tagging for the identification of common disease genes, Nat Genet, 29:233-237, 2001.
60. Thomas, D.C. The need for a systematic approach to complex pathways in molecular epidemiology, Cancer Epidemiol Biomarkers Prev, 14: 557-559, 2005.